These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35180131)

  • 21. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.
    Kitao S; Matsusue E; Fujii S; Miyoshi F; Kaminou T; Kato S; Ito H; Ogawa T
    Neuroradiology; 2013 Aug; 55(8):947-953. PubMed ID: 23673875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra.
    Liu XL; Yang LQ; Liu FT; Wu PY; Zhang Y; Zhuang H; Shi YH; Wang J; Geng DY; Li YX
    BMC Neurol; 2020 Jun; 20(1):262. PubMed ID: 32605601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromelanin Magnetic Resonance Imaging of the Substantia Nigra in Huntington's Disease.
    Leitão R; Guerreiro C; Nunes RG; Gonçalves N; Galati G; Rosário M; Guedes LC; Ferreira JJ; Reimão S
    J Huntingtons Dis; 2020; 9(2):143-148. PubMed ID: 32065802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
    Ishikuro K; Hattori N; Imanishi R; Furuya K; Nakata T; Dougu N; Yamamoto M; Konishi H; Nukui T; Hayashi T; Anada R; Matsuda N; Hirosawa H; Tanaka R; Shibata T; Mori K; Noguchi K; Kuroda S; Nakatsuji Y; Nishijo H
    Neurocase; 2021 Oct; 27(5):407-414. PubMed ID: 34503372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.
    Zecca L; Berg D; Arzberger T; Ruprecht P; Rausch WD; Musicco M; Tampellini D; Riederer P; Gerlach M; Becker G
    Mov Disord; 2005 Oct; 20(10):1278-85. PubMed ID: 15986424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.
    Walter U; Hoeppner J; Prudente-Morrissey L; Horowski S; Herpertz SC; Benecke R
    Brain; 2007 Jul; 130(Pt 7):1799-807. PubMed ID: 17329323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application value of multiparametric MRI for evaluating iron deposition in the substantia nigra in Parkinson's disease.
    Cao Q; Huang J; Tang D; Qian H; Yan K; Shi X; Li Y; Zhang J
    Front Neurol; 2022; 13():1096966. PubMed ID: 36686531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Transcranial parenchymal sonography in the diagnosis of Parkinson's disease].
    Mijajlović M; Petrović I; Stojković T; Svetel M; Stefanova E; Kostić VS
    Vojnosanit Pregl; 2008 Aug; 65(8):601-5. PubMed ID: 18751340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template.
    Jin Z; Wang Y; Jokar M; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Zhang Y; Min J; Liu F; He N; Yan F; Haacke EM
    Hum Brain Mapp; 2022 Apr; 43(6):2011-2025. PubMed ID: 35072301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Transcranial sonography of substantia nigra in patients with Parkinson's disease].
    Miwa H
    Rinsho Shinkeigaku; 2013; 53(11):981-2. PubMed ID: 24291852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated volumetric determination of high R
    Tessema AW; Lee H; Gong Y; Cho H; Adem HM; Lyu I; Lee JH; Cho H
    NMR Biomed; 2022 Nov; 35(11):e4795. PubMed ID: 35775868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Gaurav R; Yahia-Cherif L; Pyatigorskaya N; Mangone G; Biondetti E; Valabrègue R; Ewenczyk C; Hutchison RM; Cedarbaum JM; Corvol JC; Vidailhet M; Lehéricy S
    Mov Disord; 2021 Jul; 36(7):1592-1602. PubMed ID: 33751655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.
    Zhao XJ; Niu XY; You HY; Zhou M; Ji XB; Liu Y; Wu L; Ding XL
    Curr Med Sci; 2019 Oct; 39(5):831-835. PubMed ID: 31612404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.